Explore more
News
FDA, GSK and Blenrep
Digest more
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
5hon MSN
Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.
Asianet Newsable on MSN11h
GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay OptimisticThe median progression-free survival was 32.6 months on the Blenrep combo compared to 12.5 months on the alternative. While ...
The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as the agency’s Oncologic Drugs Advisory ...
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback